Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
Globe Newswire•23/10/2026•16:01 ET
0
Key Highlights
- ➤1,400+ dialysis adults saw serum phosphate reductions after tenapanor initiation
- ➤Month-six adjusted phosphate reductions ranged from 0.80 to 1.55 mg/dL
- ➤16% to 41% reached serum phosphate below 5.5 mg/dL across treatment groups
- ➤60% to 70% of patients remained on tenapanor at 180 days
- ➤Similar reductions occurred with or without a phosphate binder
Expert Statements
Rajani Dinavahi, Chief Medical Officer of Ardelyx
“These findings add meaningful real-world evidence describing serum phosphate reductions following XPHOZAH initiation in patients both with and without a phosphate binder at baseline.”
Rajani Dinavahi, Chief Medical Officer of Ardelyx
“The broader research we presented at ASN Kidney Week also highlights how persistently difficult it is for patients to manage hyperphosphatemia, and the serious mortality and morbidity risks associated with cumulative phosphate burden.”
Rajani Dinavahi, Chief Medical Officer of Ardelyx
“Taken together, these data reinforce the ongoing challenges of phosphate management and why we need more treatment options to help patients on dialysis gain control of their phosphate levels”
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated
Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus
Get started
Create a free account to read the full story.